September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
LUNGevity Foundation Highlighted FDA Approval on Telisotuzumab Vedotin (EMRELIS) in Advanced NSCLC
Jun 1, 2025, 08:52

LUNGevity Foundation Highlighted FDA Approval on Telisotuzumab Vedotin (EMRELIS) in Advanced NSCLC

LUNGevity Foundation shared a post on LinkedIn:

“Despite the progress we have seen in the treatment of lung cancer, we need more options for people whose treatments stop working,” said Upal Basu Roy, PhD, MPH, executive director of research, LUNGevity Foundation. “This approval is a welcomed targeted therapy for those with high c-Met protein overexpressing late-stage, non-small cell lung cancer who have seen very limited treatment innovation in the last decade.”

Read More on nsclc.lungevity.org.

Read OncoDaily’s Special Article: FDA Approval for Telisotuzumab Vedotin (EMRELIS™)

fda approval Telisotuzumab Vedotin LUNGevity Foundation